Stanford
http://www.stanfordgroup.com/#Stanford provides institutional investment services and private wealth management services. The firm also offers equity research to its clients in the consumer, media, energy, financial, healthcare, technology and water/environment sectors.
-
TG Therapeutics (TGTX) Announces Commercial Launch of BRIUMVI
-
TG Therapeutics (TGTX) Confirms FDA Approval of BRIUMVI (ublituximab-xiiy)
-
TG Therapeutics (TGTX) Reports Publication of Results from ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab
-
TG Therapeutics (TGTX) Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
-
TG Therapeutics (TGTX) to Present Data from ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
-
TG Therapeutics (TGTX) Announces Data for Ublituximab in MS Presented at ECTRIMS
-
TG Therapeutics (TGTX) Submits BLA to FDA for Ublituximab as Treatment for Patients with Relapsing Forms of Multiple Sclerosis
-
TG Therapeutics (TGTX) to Present Data from ULTIMATE I & II Phase 3 Trials of Ublituximab in MS at ECTRIMS
-
TG Therapeutics (TGTX) Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at EAN
-
TG Therapeutics (TGTX) Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in MS to be Presented at American Academy of Neurology 73rd Annual Meeting
-
TG Therapeutics (TGTX) ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with MS Met Primary Endpoints
-
TG Therapeutics (TGTX) Reports Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
-
TG Therapeutics (TGTX) Presents Data for Ublituximab at ECTRIMS
-
TG Therapeutics (TGTX) Provides Long-Term Follow-Up Data from Phase 2 Trial of Ublituximab in Patients with MS
-
TG Therapeutics (TGTX) Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at AAN
-
TG Therapeutics (TGTX) Announces Final Phase 2 Multiple Sclerosis Data Presentation at ACTRIMS
-
TG Therapeutics (TGTX) Highlights Final Phase 2 Multicenter Trial of ublituximab (TG-1101) in Multiple Sclerosis Data Presentation
-
TG Therapeutics (TGTX) Said Final Phase 2 MS Data Selected for Oral Presentation at ECTRIMS
-
TG Therapeutics (TGTX) Reports Complete Target Enrollment in ULTIMATE Phase 3 Trials in Multiple Sclerosis
-
TG Therapeutics (TGTX) Reports Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis
-
TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with MS at AAN
-
TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with MS at ACTRIMS
-
TG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at ECTRIMS - ACTRIMS
-
TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS
-
UPDATE: TG Therapeutics (TGTX) Secures Grant from National Multiple Sclerosis Society to Support Development of TGR-1202 (Umbralisib) as Oral B-cell Targeted Treatment Option
-
TG Therapeutics (TGTX) Says Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with RMS Are Now Open for Enrollment
-
TG Therapeutics (TGTX) Plans Data Presentations at Joint ECTRIMS - ACTRIMS Meeting
-
TG Therapeutics (TGTX) Announces SPA Agreement with FDA for Phase 3 Program of TG-1101 for Patients with Multiple Sclerosis
-
Pre-Open Stock Movers 06/01: (OMG) (ONTY) (ALTR) Higher; (CLVS) (CLD) (BTU) Lower (more...)
